{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-032004","form_type":"8-K","ticker":"SPRO","cik":"0001701108","company_name":"Spero Therapeutics, Inc.","filed_at":"2026-01-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.933732+00:00","generated_at":"2026-05-16T05:59:51.018324+00:00","sec_items":["5.02","8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Director resigns; SEC concludes investigation with no enforcement action","bullets":["Ankit Mahadevia, MD resigned from board effective Jan 30, 2026 due to other professional commitments; no dispute with company.","Company intends to enter consulting agreement with Mahadevia for continued support.","SEC concluded its investigation on Jan 20, 2026; will not recommend enforcement action against company at this time.","Investigation was previously disclosed in SEC periodic reports."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-032004","json":"https://secwatch.observer/filing/0001193125-26-032004.json","markdown":"https://secwatch.observer/filing/0001193125-26-032004.md","text":"https://secwatch.observer/filing/0001193125-26-032004.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1701108/000119312526032004/0001193125-26-032004-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1701108/000119312526032004/d55903d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T05:59:51.018324+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}